clinical trial · NCT04982354
Induction Therapy for Patients With FLT3 Mutated Acute Myeloid Leukemia
Guenther Koehne·phase2·withdrawn
Acute Myeloid LeukemiaCPX-351MidostaurinBusulfanMelphalanFludarabineCD34+ selected allogeneic stem cell transplant from an HLA-compatible donor
brief summary
This is a pilot study designed to identify the effect of daunorubicin-cytarabine liposome (CPX-351) in combination with a FLT3-inhibitor (midostaurin) as induction and consolidation therapy for patients with high-risk FLT3 mutated acute myeloid leukemia (AML) and subsequent CD34+-selected allogeneic stem cell transplant from HLA compatible related or unrelated donors.
started
Jul 5, 2022
primary completion
Aug 1, 2031
completion
Aug 1, 2032
last updated
Oct 1, 2024
official title
A Pilot Study of Daunorubicin-cytarabine Liposome (CPX-351) Plus FLT3-inhibitor (Midostaurin) as Induction Therapy for Patients With FLT3 Mutated Acute Myeloid Leukemia Followed by Consolidation With a CD34+-Selected Allograft
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol